Agreements

Date: 16th October, 2026 To, To, The Manager (Listing) Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, G Block, Dalal Street, Fort, Mumbai - 400 001 Bandra-Kurla Complex, BSE Symbol: ANUHPHR Bandra (E), Mumbai – 400051 BSE Scrip Code: 506260 NSE Symbol: ANUHPHR; Series: EQ Sub: Disclosure under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015) in respect of the execution of an Asset Transfer Agreement. Dear Sir, Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 and further to our intimation dated 13th October, 2026 we wish to inform you that Anuh Pharma Limited (“APL”) has signed the Asset Transfer Agreement (“ATA”) to purchase manufacturing facility of M/s. Vanquest Pharma Private Limited (“VPPL”) located at F-10, M.I.D.C., Tarapur, Boisar, District Palghar – 401506, Maharashtra, India. Details as required under Listing Regulations read with SEBI Circular in relation to Asset transfer is enclosed as ‘Annexure-A’ to this letter. The above information is also available on the website of the Company www.anuhpharma.com. You are requested to kindly take the same on record. Thanking you, Yours faithfully, FOR ANUH PHARMA LIMITED MANAN VADHAN COMPANY SECRETARY & COMPLIANCE OFFICER Place: Mumbai ANNEXURE - A Details as required under Regulation 30 Read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/3726 dated January 30, 2026: Particulars Disclosure a) Name(s) of parties with whom the The Company has entered into the Asset Transfer agreement is entered Agreement with Vanquest Pharma Private Limited (“VPPL”) a Private Company incorporated in India on 12/06/2019 b) Purpose of entering into the The Asset Transfer Agreement is entered into by agreement the Company for the Purchase of Assets (i.e. Land, Building, Plant & Machineries, etc.) relating to manufacturing of API’s and Intermediates. The transaction is expected to strengthen the Company's production capacity and market presence in manufacturing quality API’s and Intermediates. c) Size of agreement Said Purchase of assets is expected to increase production of the Company by 525 MTPA. Agreed value of assets purchase is Rs. 72.90 Crore. (Rupees Seventy-Two Crore Ninety Lakhs only) (Excluding applicable taxes, fees, etc.) d) Shareholding, if any, in the entity with The Company does not hold any shareholding in whom the agreement is executed Vanquest Pharma Private Limited. e) Significant terms of the agreement (in Not Applicable brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc. f) Whether, the said parties are related The counterparty is not related to the Company's to promoter/promoter group/ group promoter/promoter group or group companies. companies in any manner. If yes, nature of relationship g) Whether the transaction would fall The transaction is not a related party transaction. within related party transactions? If Particulars Disclosure yes, whether the same is done at “arm’s length” h) In case of issuance of shares to the Not Applicable. The transaction involves payment parties, details of issue price, class of of cash consideration and does not involve the shares issued issuance of any shares by the Company. i) Any other disclosures related to such There are no nominees to be appointed on the agreements, viz., details of nominee on Board of Directors of the Company pursuant to the the board of directors of the listed ATA. entity, potential conflict of interest arising out of such agreements, etc.